| Ytd | -12.70% | |
| 1y | 37.73% |
| Open | 13.78 | Prev Close | 13.76 | Low | 13.03 | High | 14.10 | Mkt Cap | 856.66M |
| Vol | 975.91K | Avg Vol | 894.05K | EPS | -1.92 | P/E | N/A | Forward P/E | -6.29 |
| Beta | 1.64 | Short Ratio | 12.92 | Inst. Own | 116.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 18.33 | 200-d Avg | 18.22 | 1yr Est | 50.13 |
Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maint
HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy an
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyosi
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile
Jade Biosciences, Inc. (NASDAQ: JBIO - Get Free Report) has received a consensus recommendation of "
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcrip
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences,
Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significan
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.76) per share which missed the analy
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week sub
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the st
Stocks to watch: CIEN, DOCU, LULU, report earnings today. MRAAF introduces world's first 100Vdc
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
Jade Biosciences NASDAQ: JBIO said interim results from a Phase 1 healthy volunteer study of JADE101
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunt
Jade Biosciences, Inc. (NASDAQ:JBIO) reported interim Phase 1 results for JADE101 in immunoglobulin
U.S. stock futures up, Nasdaq surges 0.35%, with Taylor Morrison's buyout announcement. Other pr
SAN FRANCISCO and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, In
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication p
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, In
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq
Top analysts updated ratings for MU, EPAM, WLTH, OKUR, BLDR, DMRC, JBIO, CRCL. See changes and ratin